Archive | Journals RSS for this section

Call For Papers: Pediatric Cancer special issue of the journal ‘Cold Spring Harbor Molecular Case Studies’

Cold Spring Harbor Molecular Case Studies is inviting submissions of research papers to be considered for a special issue co-edited by Drs. Elaine Mardis and Andrew Kung, on the topic of pediatric cancers, which is planned for publication in August 2019.

Existing genomic data demonstrates that at least half of the drivers of childhood cancers are unique to pediatric patients. There are thus increasing efforts to perform more comprehensive genomic and transcriptomic analyses of pediatric cancer patients, especially in rare tumor types or in relapsed/refractory patients who have failed the standard of care. These data are being applied to refine patient diagnosis, to identify prognostic markers, and to aid treatment decision-making. The forthcoming special issue of Cold Spring Harbor Molecular Case Studies will focus on this area of clinical translation, and we are encouraging submissions of research papers describing oncogenomic profiling of pediatric patients. These papers should include clinical presentation, disease-pertinent findings, treatment history and outcomes (where appropriate). We also welcome reports of pilot studies describing new clinical protocols in precision pediatric oncogenomics, or non-sequencing based technologies to more comprehensively characterize pediatric cancers, bodily fluids, or the tumor microenvironment. Suggested areas for submission include manuscripts describing genomic identification and functionalization of novel variants leading to cancer onset or progression, exceptional responders, novel treatments based on genomic profiling results and their outcome, immunogenomic applications in cancer patient care or patient monitoring, integrative analytical approaches to identify cancer vulnerabilities, and combinations of therapies indicated by genomics and other diagnostic assays.

Existing genomic data demonstrates that at least half of the drivers of childhood cancers are unique to pediatric patients. There are thus increasing efforts to perform more comprehensive genomic and transcriptomic analyses of pediatric cancer patients, especially in rare tumor types or in relapsed/refractory patients who have failed the standard of care. These data are being applied to refine patient diagnosis, to identify prognostic markers, and to aid treatment decision-making. The forthcoming special issue of Cold Spring Harbor Molecular Case Studies will focus on this area of clinical translation, and we are encouraging submissions of research papers describing oncogenomic profiling of pediatric patients. These papers should include clinical presentation, disease-pertinent findings, treatment history and outcomes (where appropriate). We also welcome reports of pilot studies describing new clinical protocols in precision pediatric oncogenomics, or non-sequencing based technologies to more comprehensively characterize pediatric cancers, bodily fluids, or the tumor microenvironment.

Suggested areas for submission include manuscripts describing genomic identification and functionalization of novel variants leading to cancer onset or progression, exceptional responders, novel treatments based on genomic profiling results and their outcome, immunogenomic applications in cancer patient care or patient monitoring, integrative analytical approaches to identify cancer vulnerabilities, and combinations of therapies indicated by genomics and other diagnostic assays.

Cold Spring Harbor Molecular Case Studies is an open-access, peer-reviewed, international journal in the field of precision medicine. Articles in the journal present genomic and molecular analyses of individuals or cohorts alongside their clinical presentations and phenotypic information. The journal’s purpose is to rapidly share insights into disease development and treatment gained by application of genomics, proteomics, metabolomics, biomarker analysis, and other approaches. It has a rapid peer-review process that is based on technical evaluation of the analyses performed, not the novelty of findings, and offers a swift, clear path to publication. We expect to coordinate the publication of these papers with commissioned front matter in the pediatric oncogenomics special issue. Accepted manuscripts will be published as Advance Online Articles in Molecular Case Studies prior to the Special Issue print publication. If you would like your work to be considered, please submit your manuscript online on or before June 15, 2019 at submit.molecularcasestudies.org.

Visit CSH Molecular Case Studies online for additional information about the journal and manuscript formats. For more information about submitting manuscripts to Molecular Case Studies for this Special Issue, please contact Elaine Mardis (elaine.mardis@nationwidechildrens.org), Andrew Kung (kunga@mskcc.org), or Laureen Connell (connell@cshl.edu).

CALL FOR PAPERS: CLINICAL RESEARCH AND CLINICAL TRIALS

Current Oncology is seeking high-quality original clinical research and clinical trial articles. Areas may include research related to treatment, prevention, diagnostic, screening, and quality of life. Articles submitted should contain information that is relevant directly to clinical oncology practice, and have clear potential for application to the current or future practice of cancer medicine. Current Oncology is the only Canadian peer-reviewed publication and is the authoritative resource for high-impact Canadian oncology research.

ABOUT CURRENT ONCOLOGY

  • Peer reviewed journal with focus on Canadian Oncology practice and studies of international significance
  • Open Access publication with full text articles freely available at www.current-oncology.com
  • Distributed in print gratis to the Canadian oncology community
  • Broad reach, with over 30,000 average page views per month, from over 190 countries
  • Indexed and listed in PubMed, PubMed Central and MEDLINE®
  • Impact Factor of 2.048

WHY PUBLISH WITH CURRENT ONCOLOGY?

  • High standard of peer review
  • Highest editorial standards and editing services to improve your accepted manuscript’s accuracy and readability
  • Quick publication timelines
  • Articles widely promoted through email notifications, table of contents alerts, and social media
  • Authors are granted specific rights for a large number of author uses

SUBMISSION GUIDELINES

Manuscripts may be submitted electronically through our online submission and peer review system. For information about preparing your manuscript for submission, visit our “Information for Authors” page at www.current-oncology.com.

QUESTIONS?

Contact Karen Irwin: current_oncology@multi-med.com